Clinical trials: Acquired Immune Deficiency Syndrome Virus
HIV, AIDS
Efficacy and Safety of Immune Checkpoint Inhibitors for Refractory Opportunistic Infections in AIDS
This prospective, single-arm, open-label study aims to evaluate the efficacy and safety of a PD-1 inhibitor (Sintilimab) combined with standard anti-infective therapy in patients with advanced HIV disease (AHD) who are suffering…
- Conditions
- HIV, AIDS, Immune Checkpoint Inhibitors, Refractory Opportunistic Infection
- Trial name
- NCT07579247
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Public Health Clinical Center
HIV Infections
Fostemsavir Compassionate Use Named Patient Program for the Treatment of Human Immunodeficiency Virus 1 (HIV-1)
Compassionate use access to fostemsavir (GSK3684934, formerly BMS-663068) for the treatment of HIV infection in individuals with multidrug resistant HIV-1 infection who are experiencing virologic failure and are unable to…
- Trial name
- NCT04233047
- Testing
- Fostemsavir
- Sponsor
- ViiV Healthcare
Pneumonia, Pneumocystis Carinii, HIV Infections
A Controlled Trial Comparing the Efficacy of Aerosolized Pentamidine and Parenteral/Oral Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia in AIDS
To compare the safety and effectiveness of drug therapy with aerosolized pentamidine (PEN) with that of conventional therapy, sulfamethoxazole plus trimethoprim (SMX/TMP) in the treatment of Pneumocystis carinii pneumonia (PCP)…
- Trial name
- NCT00000715
- Testing
- Pentamidine isethionate, Sulfamethoxazole-Trimethoprim
- Where
- 9 sites in United States
- Volunteers
- 240 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HCV, HBV
HCV, HBV, HIV Testing During Consultation With Anesthesiologist
The aim of the study is to assess the feasibility of HCV, HBV, HIV testing (according to the national guidelines) during consultation with Anesthesiologist before a planned surgery in Lariboisiere Hospital, Paris, France.
- Conditions
- HCV, HBV, Hiv
- Trial name
- SAHARA (NCT04286347)
- Testing
- HCV, HBV, HIV tests
- Where
- France
- Volunteers
- 363 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cytomegalovirus Retinitis, HIV Infections
An Open Label Evaluation of the Safety and Pharmacokinetics of Ganciclovir in Children
To evaluate the pharmacokinetics of intravenous ganciclovir in children (ages 3 months - 12 years). To determine the safety and tolerance of a 2 to 3 week induction course of ganciclovir IV in immunocompromised children receiving…
- Trial name
- NCT00002015
- Testing
- Ganciclovir
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- Roche Global Development
HIV
A Study to Assess the Long-term Safety and Tolerability of TMC114/Rtv in HIV-1 Infected Participants After Rolling-over From Other TMC114 Trials
The purpose of this study was primarily to assess the long-term safety and tolerability of TMC114/rtv in addition to an individually optimized background antiretroviral therapy in HIV-1 infected participants.
- Trial name
- NCT02187107
- Testing
- TMC114, rtv
- Where
- 11 sites in Australia, Austria and 6 more
- Volunteers
- 52 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Infections
New Era Study: Treatment With Multi Drug Class (MDC) HAART in HIV Infected Patients
This is a multi-center, open-label, non-randomized proof-of-concept trial. Two cooperating HIV-specialized centres represented by Dr. med. Hans Jaeger and Prof. Dr.
- Trial name
- NewEra (NCT00908544)
- Testing
- PHI-patients, CHI-patients
- Where
- 8 sites in Germany
- Volunteers
- 47 people
- Sponsor
- MUC Research GmbH
HIV Infections, HIV-Associated Lipodystrophy Syndrome
A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth
The purpose of this study is to assess the prevalence of metabolic and physical abnormalities in HIV infected (via mother-to-child transmission) and uninfected children and youth.
- Conditions
- HIV Infections, HIV-Associated Lipodystrophy Syndrome, HIV Lipodystrophy Syndrome, Lipodystrophy
- Trial name
- NCT00069004
- Where
- 38 sites in United States, Puerto Rico
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Infants and Children Infected With or at Risk for HIV Infection
AMENDED: As of 10/19/90 only Children 0 to 3 months are being enrolled. Original design: To determine whether the experimental drug recombinant CD4 (rCD4), which is produced through genetic engineering technology, is safe and…
- Trial name
- NCT00000984
- Testing
- CD4 Antigens
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV/AIDS
PrEP My Way: A Hybrid Type 1 Clinical Effectiveness-implementation Trial to Promote PrEP Persistence Among Young Kenyan Women
PrEP My Way is a novel PrEP delivery system consisting of clinic-based PrEP initiation, followed by peer-delivered kits for HIV self-testing, PrEP refills, vaginal swabs for gonorrhea and chlamydia self-sampling, pregnancy tests…
- Trial name
- NCT06566430
- Testing
- PrEP My Way intervention, PrEP My Way intervention without STI testing, Enhanced standard of care
- Where
- Kenya
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Infection, Human Immunodeficiency Virus
A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)
This is an open-label, single sequence, 2-cohort, drug-drug interaction study in healthy male and female subjects. There is no formal hypothesis, however, it is expected that the coadministration of BMS-663068 with darunavir…
- Trial name
- NCT02277600
- Testing
- BMS-663068, Darunavir, Cobicistat
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Human Immunodeficiency Virus, Tuberculosis
Usability Study of IeHS in Indonesia
Technology that has a particular focus on patients' needs and ease-of-use and -access plays a significant role in the development of e-health and m-health.
- Conditions
- Human Immunodeficiency Virus, Tuberculosis, Interpersonal Relations, Mobile Phone Use
- Trial name
- NCT04179344
- Testing
- Integrated e-healthcare services (IeHS) web-based app
- Where
- 3 sites in Indonesia
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Bekasi City Public Hospital
Infection, Human Immunodeficiency Virus
A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
This study is a 48-week, Phase IIIb, randomly assigned, open-label, active-controlled, multicenter, parallel group, non-inferiority study.
- Trial name
- NCT02105987
- Testing
- ABC/DTG/3TC FDC, Ongoing cART regimen
- Where
- 103 sites in United States, Canada and 1 more
- Volunteers
- 555 people
- Sponsor
- ViiV Healthcare
HIV/AIDS, Violence
Effectiveness of Transdiagnostic Cognitive Behavioral Therapy for Improving HIV Treatment Outcomes in South Africa
This study will evaluate the impact of the Common Elements Treatment Approach (CETA), an evidence-based intervention comprised of cognitive-behavioral therapy elements, at improving HIV treatment outcomes among women with HIV who…
- Trial name
- CETA (NCT04242992)
- Testing
- CETA, Short Message Service (SMS) text reminders
- Where
- South Africa
- Volunteers
- 399 people, healthy volunteers welcome
- Sponsor
- Boston University
Infection, Human Immunodeficiency Virus
Dolutegravir Renal Impairment Study
Dolutegravir (DTG, GSK1349572) is an integrase inhibitor being developed for the treatment of human immunodeficiency virus (HIV)-1 infection by GlaxoSmithKline (GSK) on behalf of Shionogi-ViiV Healthcare LLC.
- Trial name
- NCT01353716
- Testing
- Dolutegravir 50 mg
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV/AIDS
Community Health Workers And MHealth to ImProve Viral Suppression Plus (CHAMPS+)
Although global efforts have been made to end the HIV epidemic, there are still some gaps in HIV testing, antiretroviral therapy (ART) adherence, and viral suppression (VS) among people with HIV (PWH).
- Trial name
- CHAMPS+ (NCT06472206)
- Testing
- CHW Sessions, CleverCap
- Where
- 5 sites in United States
- Volunteers
- 420 people
- Sponsor
- Columbia University
HIV/AIDS
Adolescent Coordinated Transition Nigerian HIV+ Youth
The purpose of this study is to evaluate the comparative effectiveness of a comprehensive, coordinated transition protocol which includes an early introduction to the adult provider, an integrated case management team and a…
- Trial name
- ACT (NCT03152006)
- Testing
- ACT
- Where
- 5 sites in Nigeria
- Volunteers
- 216 people
- Sponsor
- University of Nevada, Las Vegas
Human Immunodeficiency Virus
Pilot Test of a Couple-Based Medication Adherence Intervention for HIV-Positive Women and Their Male Partners in South Africa
The purpose of this study is to collect quantitative data related to developing and testing a couple-based intervention (CBI) for HIV-positive women's medication adherence in the region of Kwazulu-Natal, South Africa.
- Trial name
- NCT03809364
- Testing
- START Together
- Where
- South Africa
- Volunteers
- 40 people
- Sponsor
- University of Maryland, College Park
Infections, Human Immunodeficiency Virus and Herpesviridae
GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir
GSK1349572 is an integrase inhibitor being developed for the treatment of human immunodeficiency virus (HIV)-1 infection by GlaxoSmithKline (GSK) on behalf of Shionogi-ViiV HealthcareLLC.
- Trial name
- NCT01209065
- Testing
- GSK1349572, Fosamprenavir, Ritonavir
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV - Human Immunodeficiency Virus
Improving Management of Recipients of Care With HIV Viremia to Optimize Viral Suppression in Zambia: A Process and Outcome Evaluation
The Centre for Infectious Disease Research in Zambia (CIDRZ) as an implementing partner (IP) through its Centers for Disease Control and Prevention (CDC) and President's Emergency Plan for AIDS Relief (PEPFAR)-funded programs…
- Trial name
- NCT07747987
- Testing
- additional support
- Where
- Zambia
- Volunteers
- 548 people
- Sponsor
- Centre for Infectious Disease Research in Zambia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.